Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Neovasc Inc. (NVCN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.53-0.31 (-5.31%)
At close: 04:00PM EDT
5.34 -0.19 (-3.44%)
After hours: 05:53PM EDT
Advertisement

Neovasc Inc.

13562 Maycrest Way
Suite 5138
Richmond, BC V6V 2J7
Canada

https://www.neovasc.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees49

Key Executives

NameTitlePayExercisedYear Born
Mr. Fredericus A. ColenPres, CEO & Director2.59MN/A1952
Mr. Christopher Clark B.A., BA (Honours), C.A., CA, PgDCFO & Corp. Sec.1.09MN/A1972
Mr. William Reed LittleChief Operating Officer1.2MN/A1971
Mr. John Christopher PantonChief Quality Officer388.39kN/A1967
Sarah Marie-Hodgson GallagherVP of Clinical Affairs378.54kN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.

Corporate Governance

Neovasc Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement